Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PYC Therapeutics Limited ( (AU:PYC) ) has provided an announcement.
In its fourth-quarter 2025 update, PYC Therapeutics reported continued progress across all four of its pipeline programs, highlighting key clinical milestones and positioning the company for important safety and efficacy read-outs over the next two years. The company established a favourable safety and tolerability profile for its polycystic kidney disease candidate in healthy volunteers, clearing the way for progression to patient studies; advanced its autosomal dominant optic atrophy program into a global repeat-dose trial aimed at demonstrating clinical proof of concept; presented longer-term data showing sustained vision improvement in patients with retinitis pigmentosa type 11 treated with its investigational therapy; and showcased preclinical data, including non-human primate results, to support moving its Phelan-McDermid syndrome candidate into clinical trials. Collectively, these developments underscore PYC’s execution against its clinical roadmap and strengthen its positioning as an emerging player in RNA therapeutics for high-unmet-need genetic diseases.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a precision medicine biotechnology company developing RNA-based therapeutics for patients with severe genetic diseases that currently have no treatment options. The company is advancing a pipeline of four first-in-class drug candidates, three of which are already in human trials, targeting indications where RNA therapeutics can directly address underlying genetic causes, including diseases driven by haploinsufficiency.
Average Trading Volume: 470,837
Technical Sentiment Signal: Buy
Current Market Cap: A$979.9M
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.